Table 2 Factors associated with the likelihood of developing pulmonary hypertension
From: Pulmonary arterial hypertension associated with interferon therapy: a population-based study
Patient characteristics | Hazard ratio (95% CI) |
|---|---|
Indication for interferon | |
Multiple sclerosis | Reference |
Hepatitis C | 1.43 (0.69, 2.96) |
Age | |
20–29 | Reference |
30–39 | 0.26 (0.02, 4.23) |
40–49 | 1.46 (0.19, 11.19) |
50–59 | 2.41 (0.32, 18.29) |
60–65 | 4.05 (0.49, 33.36) |
Gender | |
Male | Reference |
Female | 1.02 (0.62, 1.68) |
Comorbidity, Yes vs No | |
Hypertension | 1.43 (0.84, 2.43) |
Other liver diseasea | 3.21 (1.93, 5.34) |
Diabetes | 2.27 (1.25, 4.11) |
Chronic pulmonary disease | 1.92 (0.82, 4.50) |
Sleep apnea | 1.31 (0.31, 5.56) |
Connective tissue disorder | 4.32 (1.71, 10.96) |
Obesity | 0.73 (0.10, 5.51) |
HIV/AIDS | 2.63 (0.63, 10.89) |
Valvular disease | 3.76 (1.16, 12.21) |
Congestive heart failure | 1.10 (0.15, 8.17) |